The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease.
Alzheimers Dement
; 17(7): 1145-1156, 2021 07.
Article
em En
| MEDLINE
| ID: mdl-33491853
ABSTRACT
INTRODUCTION:
This study investigated the diagnostic and disease-monitoring potential of plasma biomarkers in mild cognitive impairment (MCI) and Alzheimer's disease (AD) dementia and cognitively unimpaired (CU) individuals.METHODS:
Plasma was analyzed using Simoa assays from 99 CU, 107 MCI, and 103 AD dementia participants.RESULTS:
Phosphorylated-tau181 (P-tau181), neurofilament light, amyloid-ß (Aß42/40), Total-tau and Glial fibrillary acidic protein were altered in AD dementia but P-tau181 significantly outperformed all biomarkers in differentiating AD dementia from CU (area under the curve [AUC] = 0.91). P-tau181 was increased in MCI converters compared to non-converters. Higher P-tau181 was associated with steeper cognitive decline and gray matter loss in temporal regions. Longitudinal change of P-tau181 was strongly associated with gray matter loss in the full sample and with Aß measures in CU individuals.DISCUSSION:
P-tau181 detected AD at MCI and dementia stages and was strongly associated with cognitive decline and gray matter loss. These findings highlight the potential value of plasma P-tau181 as a non-invasive and cost-effective diagnostic and prognostic biomarker in AD.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Encéfalo
/
Biomarcadores
/
Peptídeos beta-Amiloides
/
Proteínas tau
/
Doença de Alzheimer
/
Disfunção Cognitiva
Tipo de estudo:
Diagnostic_studies
/
Prognostic_studies
Limite:
Aged
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Alzheimers Dement
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Suécia